Engineering precision nanoparticles for drug delivery
By Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, M. Wechsler, Nicholas A. Peppas, Robert Langer. Nature reviews. Drug discovery, 2020
6,130 citations recorded by the source corpus.
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall. Advances in nanoparticle design could make substantial contributions to personalized and non-personalized medicine. In this Review, Langer, Mitchell, Peppas and colleagues discuss advances in nanoparticle design that overcome heterogeneous barriers to delivery, as well as the challenges in translating these design improvements into personalized medicine approaches.
Subfields: Biomaterials, Molecular Biology, Pharmaceutical Science
View Paper: https://www.semanticscholar.org/paper/cac88108ed7a7457463d7c5ede9c7db3b249f93b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Yajun Wang
- T. Gong
- Yongliang Cao
- Yongkai Cao
- Dahua Fan
- Meiqun Cao
Citations in the corpus
- Nanomedicine in cancer therapy (2023, background): “25 Tumor tissue targeting is mainly achieved by exploiting the leaky tumor vasculature and de fi cient tumor lymphatic system, which allow nanoscale particles to passively accumulate in solid tumors through the enhanced permeability and retention (EPR) effect.”